Neurophysiology

3Brain AG CorePlate™ technology combines microchips and AI in a revolutionary new approach to drug discovery

Retrieved on: 
Tuesday, June 8, 2021
Health sciences, Branches of biology, Pharmaceutical sciences, Pharmaceutical industry, Electrophysiology, Microelectrode array, Neurophysiology, Physiology, MEA, Medication, Drug discovery

3Brain AG unveils groundbreaking CorePlatetechnology to allow the harvesting of big data on drug candidates before testing on humans to increase the chance of pharmaceutical success.

Key Points: 
  • 3Brain AG unveils groundbreaking CorePlatetechnology to allow the harvesting of big data on drug candidates before testing on humans to increase the chance of pharmaceutical success.
  • The CorePlate technology devised by 3Brain disrupts this paradigm by bringing the processing unit in contact with the cells.
  • With the CorePlate technology, pharmaceutical companies can save time and money by better filtering and prioritizing drug candidates.
  • After being the first to introduce CMOS-based HD-MEA (high-density microelectrode array), 3Brain is now setting up the next standard with the mentioned CorePlate technology.

BrainsWay to Present at the Raymond James Human Health Innovation Conference

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Tel Aviv Stock Exchange

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:
    Clinical TMS Society Annual Meeting from June 10-12.
  • The Annual Meeting of the Clinical TMS Society provides a unique opportunity to connect with TMS providers and researchers from around the world.
  • Additionally, the Company will be hosting two showcase presentations featuring novel research and the clinical utility of Deep TMS.
  • Psych Congress Elevate: Virtual Experience from June 11- 13.

Delix Therapeutics Announces Scientific & Strategic Advisory Board Appointments

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Neuroscience, Biology, Nervous system, Neurology, Neurophysiology, Psychiatry

BOSTON, June 4, 2021 /PRNewswire/ --Delix Therapeutics (the "Company"), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced the inaugural members of its Scientific and Strategic Advisory Board.

Key Points: 
  • BOSTON, June 4, 2021 /PRNewswire/ --Delix Therapeutics (the "Company"), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced the inaugural members of its Scientific and Strategic Advisory Board.
  • Headquartered in Massachusetts, Delix is creating a new class of neuroplasticity-promoting therapeutics known as psychoplastogens.
  • The inaugural Scientific and Strategic Advisory Board team will contribute by applying cutting-edge knowledge and scientific rigor to advance the understanding of how non-hallucinogenic analogs of psychedelic compounds can be developed into safe, FDA-approved medicines for the treatment of central nervous system-related conditions.
  • "Delix is well on its way to becoming a leading neuroscience company," said Advisory Board member Michael Cola.

NeuroOne Introduces Advisory Board for Ablation Electrode Technology that Records and Ablates Brain Tissue Linked to Seizure Activity

Retrieved on: 
Wednesday, June 2, 2021
Branches of biology, Neuroscience, Neurotechnology, Neurophysiology, Brain–computer interfacing, Emerging technologies, Electrophysiology, Electroencephalography, Neurology, Human brain, Cortical stimulation mapping

Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure.

Key Points: 
  • Their experience in the field will be indispensable to the Company in developing a product that allows neurologists to record brain activity and ablate targeted brain tissue in the same procedure.
  • The electrode is also expected to save time, cost and potentially improve outcomes, adding value to both patients and physicians that could benefit from this technology."
  • In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015.
  • NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson's disease, epilepsy and pain management due to failed back surgery procedures.

BrainsWay Announces First Draft Proposal for OCD Coverage by a Regional Medicare Administrative Contractor

Retrieved on: 
Tuesday, June 1, 2021
Branches of biology, Neuroscience, Medicine, Neurophysiology, Neuropsychology, Neurotechnology, Treatment of depression, Brainsway, Transcranial magnetic stimulation, Obsessive–compulsive disorder, Osteochondritis dissecans

The BrainsWay team has worked closely with the MACs, and specifically Palmetto, to provide the appropriate published clinical literature for Deep TMS in support of this proposed draft LCD.

Key Points: 
  • The BrainsWay team has worked closely with the MACs, and specifically Palmetto, to provide the appropriate published clinical literature for Deep TMS in support of this proposed draft LCD.
  • We look forward to the formal policy from Palmetto, and anticipate that other MACs, over time, will also issue their draft policies for Deep TMS coverage of OCD.
  • We remain committed to working to secure further coverage policy decisions from additional payors in the coming months.
  • The patient selection criteria identified in Palmettos draft LCD is closely aligned with the Clinical TMS Societys recommended OCD coverage policy.

NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults

Retrieved on: 
Tuesday, June 1, 2021
Branches of biology, Biology, Neurophysiology, Electrophysiology, Integral membrane proteins, Geriatrics, Rehabilitation medicine, Sarcopenia, Ion channel, Neuromuscular junction

NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.

Key Points: 
  • NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.
  • This study is intended to establish whether NMJ transmission deficits occur in sarcopenic individuals, and to investigate whether these deficits correlate with reduced physical performance.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: This is the first clinical study that NMD Pharma has coordinated in older adults with sarcopenia.
  • We are grateful to the world-leading clinical teams in Ohio, and their prospective study participants, for making this study possible.

NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults

Retrieved on: 
Tuesday, June 1, 2021
Branches of biology, Biology, Neurophysiology, Electrophysiology, Integral membrane proteins, Geriatrics, Rehabilitation medicine, Sarcopenia, Ion channel, Neuromuscular junction

NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.

Key Points: 
  • NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.
  • This study is intended to establish whether NMJ transmission deficits occur in sarcopenic individuals, and to investigate whether these deficits correlate with reduced physical performance.
  • Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: This is the first clinical study that NMD Pharma has coordinated in older adults with sarcopenia.
  • We are grateful to the world-leading clinical teams in Ohio, and their prospective study participants, for making this study possible.

American College of Lifestyle Medicine Announces Addition of Global Mental Well-Being Leader The Lift Project to its Corporate Roundtable

Retrieved on: 
Thursday, May 27, 2021
Branches of biology, Neuroscience, Biology, Nervous system, Neurology, Neurophysiology, Psychiatry, Psychology

ACLM launched its Corporate Roundtable in 2016 and has grown to include more than 30 active member organizations in the lifestyle medicine ecosystem.

Key Points: 
  • ACLM launched its Corporate Roundtable in 2016 and has grown to include more than 30 active member organizations in the lifestyle medicine ecosystem.
  • Founded in Australia by internationally recognized lifestyle medicine expert Dr. Darren Morton, The Lift Project is an evidence-based program employing strategies from lifestyle medicine, positive psychology and neuroscience.
  • The Lift Project is bringing lifestyle medicine to the frontline in addressing the mental health epidemic."
  • ABOUT THE LIFT PROJECT: The Lift Project is a profit-for-purpose enterprise, driven by the mission to lift 10 million lives.

NYU Langone Health Launches At-Home Virtual Brain Stimulation Program

Retrieved on: 
Wednesday, May 26, 2021
Branches of biology, Medicine, Neurostimulation, Neurotechnology, New York University, Biology, Electrotherapy, Neurophysiology, Transcranial direct-current stimulation, TDCS, NYU Langone Health, Langone

NEW YORK, May 26, 2021 /PRNewswire/ -- NYU Langone Health today announced a new at-home service for transcranial direct current stimulation (tDCS)a type of noninvasive brain stimulationcurrently available to patients in almost every state.

Key Points: 
  • NEW YORK, May 26, 2021 /PRNewswire/ -- NYU Langone Health today announced a new at-home service for transcranial direct current stimulation (tDCS)a type of noninvasive brain stimulationcurrently available to patients in almost every state.
  • The first program of its kind, NYU Langone's tDCS Program provides virtual treatment for a range of cognitive, motor, speech, or mood symptoms that can occur in an array of neurological and psychiatric conditions.
  • Patients enrolled in the tDCS Program connect to the video visits using the free NYU Langone Health app .
  • All virtual healthcare technology is built into NYU Langone's website and the freeNYU Langone Health app, where patients have a central point of access for all of their healthcare needs by logging in with their NYU Langone Health MyChart account .